B-Cell

Update: B-Cells in Rheumatic Disease

Volume 2 | April 1, 2006 - June 30, 2006

Print this Content

 

 

Return to B-Cell Literature Review Index

Highest Rated Articles

Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: Emerging Patterns and Paradigms. Arthritis Rheum 2006;54:2356-67.

In this article, Dr. Gregg Silverman reviews the current literature regarding how the actions of anti-CD20 treatment on B-cell depletion and reconstitution may impact the immune system. This is explored by examining factors that influence depletion, the pattern of B-cell depletion and reconstitution, and questions regarding how B-cell depleting therapies affect lymphocytes in tissue. This excellent article clearly and concisely summarizes these topics in a format that is useful for practicing physicians who seek to better understand the possible mechanisms of B-cell directed therapies as well as for scientists working in this field.


Roll P, Palanchamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD-20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54:2377-86.

In this study, Roll and colleagues sought to delineate the regeneration profile of B-cell subsets in the peripheral blood after anti-CD-20 treatment. From serial analyses in 27 patients treated with anti-CD-20, a characteristic pattern of B cell regeneration was seen in which immature B cells (CD38high, IgD+, CD10+,CD24high) were the first to return followed by naïve B cells. CD27+ memory B cells had a slow and delayed repopulation with the level staying significantly reduced for more than 2 years. This study provides important information on the immunobiologic changes in B cell depletion and reconstitution that occurs following anti-CD-20 therapy.


Other Rated Articles

Blood

Three Stars Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 107(8):3053-7, 2006 Apr 15.

Journal of Immunology

Four Stars Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. Journal of Rheumatology. 33(5):1021-6, 2006 May.
 
Copyright © 2000-2017 The Cleveland Clinic Foundation. All Rights Reserved.
Center for Continuing Education | 1950 Richmond Road, TR204, Lyndhurst, OH 44124
Copyright © 2000-2017 The Cleveland Clinic Foundation. All Rights Reserved.
Center for Continuing Education | 1950 Richmond Road, TR204, Lyndhurst, OH 44124